UBS Group
ESLAW icon

UBS Group’s Estrella Immunopharma Warrant ESLAW Stock Holding History

UBS Group’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,285
Closed -$67 – 10677
2025
Q3 		$67 Sell
1,285
-47
-4% -$2 ﹤0.01% 9983
2025
Q2 		$47 Sell
1,332
-3,121
-70% -$157 ﹤0.01% 10059
2025
Q1 		$343 Buy
+4,453
New +$380 ﹤0.01% 9816
2024
Q3 		– Sell
-5,090
Closed -$183 – 9637
2024
Q2 		$183 Buy
+5,090
New +$265 ﹤0.01% 9090
2023
Q3 		– Sell
-200
Closed -$8 – 9584
2023
Q2 		$8 Buy
+200
New +$14 ﹤0.01% 8748
2022
Q4 		– Sell
-1,392
Closed – – 10818
2022
Q3 		$0 Hold
1,392
– – ﹤0.01% 10485
2022
Q2 		$0 Buy
1,392
+1,200
+625% +$266 ﹤0.01% 10466
2022
Q1 		$0 Sell
192
-8
-4% -$2 ﹤0.01% 10414
2021
Q4 		$0 Buy
+200
New +$99 ﹤0.01% 10366

Other funds holding ESLAW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

UBS Group's ESLAW Position: Q4 2025 in Review

UBS Group sold out of Estrella Immunopharma Warrant (ESLAW) in Q4 2025, closing a stake of 1,285 shares — an estimated $67 sold.

UBS Group first reported a position in ESLAW in Q4 2021 and held it in 9 quarters. The position peaked at $343 in Q1 2025. 9 funds tracked by Wall St. Rank hold ESLAW as of Q4 2025.

  • UBS Group reported no remaining Estrella Immunopharma Warrant position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 1,285 Estrella Immunopharma Warrant shares in Q4 2025, an estimated $67.
  • UBS Group first reported a position in Estrella Immunopharma Warrant in Q4 2021 and held it in 9 quarters.
  • UBS Group's Estrella Immunopharma Warrant position peaked at $343 in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.